American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

HIMS stock crashes 25% on Friday after this key FDA update

by admin February 22, 2025
February 22, 2025
HIMS stock crashes 25% on Friday after this key FDA update

Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01.

The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk’s weight-loss drugs.

Despite this setback, HIMS stock had surged 43% in the past five days leading up to the FDA’s announcement, making today’s sharp drop a reversal of those recent gains.

HIMS stock was down around 21% to trade at $52.25 at the time of writing.

Novo Nordisk shortage problems resolve

The decision is expected to impact the availability of cheaper, compounded versions of Ozempic and Wegovy that telehealth companies like Hims & Hers Health have been offering.

The resolution could limit how telehealth programs provide cheaper compounded versions of weight-loss and diabetes drugs, coming two months after regulators stated there was no shortage of Eli Lilly’s treatments.

Compounded drugs—custom formulations made by mixing or altering ingredients—have surged in demand in the US due to tight supplies of blockbuster medications from Novo Nordisk and Eli Lilly.

Regulations permit compounding pharmacies to replicate brand-name drugs only when shortages exist and prohibit them from producing these drugs “regularly or in inordinate amounts.”

Companies such as Hims & Hers offer compounded semaglutide, the active ingredient in Ozempic and Wegovy.

While pharmacies may still create alternative formulations by adjusting doses or modifying ingredients, the decision is a setback for companies like Hims & Hers Health, which had benefited from offering these compounded versions.

Recent acquisitions from Hims and Hers

In separate news, the company today announced the acquisition of a US-based peptide facility in California, further verticalizing its long-term ability to deliver personalized medications.

The acquisition aims to enhance supply chain durability and meet the rising demand for personalized healthcare solutions in the US.

This move follows the company’s previous acquisitions of 503A and 503B facilities, reinforcing its domestic manufacturing capabilities and improving oversight on cost, availability, and quality.

Additionally, the peptide innovation capabilities from this acquisition will allow Hims & Hers to explore preventive health, metabolic optimization, cognitive performance, and recovery science in the coming years.

Earlier in the week, Hims & Hers Health announced the acquisition of Trybe Labs, a New Jersey-based at-home lab testing facility, further expanding its diagnostic and personalized healthcare capabilities.

The acquisition will enable Hims & Hers to offer at-home blood draws and more comprehensive pretreatment testing, providing an alternative to established blood-drawing services like Labcorp and Quest Diagnostics.

While financial terms were not disclosed, the company stated that the deal was funded through cash on hand.

The acquisition will enhance testing capabilities for LDL cholesterol, lipoprotein(a), cholesterol, and apolipoprotein.

It will also support expanded care access for conditions such as low testosterone, perimenopausal and menopausal support.

The post HIMS stock crashes 25% on Friday after this key FDA update appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Onwards and upwards?
next post
Dow, S&P 500 slide as volatile week nears end: Celsius soars, UNH stock crashes

Related Posts

Asian markets celebrate Trump’s ceasefire call; Kospi 100...

June 24, 2025

Asian stocks on Feb 13: Hang Seng, Nikkei...

February 13, 2025

Europe markets open: stocks hold steady as German...

May 14, 2025

Amazon says more packages are arriving in a...

May 2, 2024

Don’t freak out about the stock market’s inflation...

February 17, 2024

FTSE 100 Index V-shaped recovery faces crucial test

June 13, 2025

Golub Capital stock could benefit from HPS Investment...

October 25, 2024

Savings drained and living off $2,400 a month,...

July 19, 2024

Trump-linked WLFI secures $590 million, claiming a spot...

March 15, 2025

Dow sinks over 400 points, S&P retreats from...

February 21, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Kraft Heinz plans breakup, weighs $20 billion grocery spin-off: report

      July 13, 2025
    • Trump’s 50% tariff on Brazil imports to brew trouble for Starbucks and Dutch Bros

      July 13, 2025
    • US to announce 30% tariff on EU and Mexico says Trump

      July 13, 2025
    • Why India is rushing to build bigger banks and what’s standing in the way

      July 13, 2025
    • Wall Street braces for weakest earnings season since 2023 amid market highs

      July 13, 2025

    Categories

    • Business (3,388)
    • Investing (2,615)
    • Latest News (2,017)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved